Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
432 Views
Emedinexus 29 May 2025
The U.S. FDA has approved Yutrepiainhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Yutrepia is a dry powder formulation of the prostacyclin analog treprostinil, offering a targeted inhaled therapy to improve exercise capacity in affected patients.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}